Collegium Pharma (COLL) Stock Price, Quote & News

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-dete...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 713 3699

Website: www.collegiumpharma.com

Address:

100 Technology Center Drive, Suite 300, Stoughton, United States

jewell69 Jan. 13 at 1:59 AM

Did everyone see that $BEAM was up 22.5% today 1/12/26 Now, new topic, thinking about $COLL losing -4.5% around Wednesday 1/7/26 Worth a trade if it hasn’t yet regained that dip ditto $BX

0 · Reply

jewell69 Jan. 9 at 6:34 PM

$COLL s 39. 46.04 around 22:50 pm 1/9 Day trade 4 small profit

0 · Reply

jewell69 Jan. 9 at 4:18 PM

$COLL re-entry (sticker shock ) 01/09/2026 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 40 $45.29 -$1,811.60 10/03/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $34.70 $0.03 $6,939.97 10/02/2025 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $34.30 -$6,860.00

0 · Reply

jewell69 Jan. 9 at 3:58 PM

$COLL I used to joke "got opium" because they sell pain medicine. ok, trying to buy, it is still up tons despite being down -6.3% today 1/9/26 Buy 40 COLL @ Limit $45.29, Day Estimated amount $1,811.60 Estimated commission $0.00 Estimated industry fee $0.00 Estimated total amount $1,811.60

0 · Reply

jewell69 Jan. 9 at 3:54 PM

$COLL Truist raised the firm’s price target on Collegium Pharmaceutical (COLL) to $55 from $47 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.

0 · Reply

jewell69 Jan. 9 at 3:50 PM

$COLL JORNAY PM = their ADHD drug "The outstanding performance of Jornay PM, along with sustained revenue growth across our pain portfolio, has put us in a strong financial position as we enter the year ahead."Co is on track to achieve recently increased financial guidance for 2025 and expects additional topline revenue growth in 2026 to be driven largely by increasing Jornay PM sales.

0 · Reply

jewell69 Jan. 9 at 3:47 PM

$COLL -6.95% this morning 1/9/26 COMPARE TO +6% ON 12/24/25 Barclays cuts target price to $56 from $58 * Collegium Pharmaceutical Inc : H.C. Wainwright ups target price to $60 from $46 * Collegium Pharmaceutical Inc : Needham raises target price to $56 from $48 *

0 · Reply

Stefan100 Dec. 30 at 2:28 PM

$COLL refinancing of term loan. Lowering rate by 175bps to SOFR + 2.75%. On around $600MM that’s 11mm or so. Very million helps… https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-closing-980-million-syndicated-credit

1 · Reply

jewell69 Dec. 25 at 1:17 AM

$COLL did everybody see it was up 6.5% today 12/24/25

2 · Reply

volflux Dec. 18 at 12:55 PM

$COLL

0 · Reply

Collegium Provides 2026 Financial Guidance and Business Update

Dec 30, 2025, 8:00 AM EST - 15 days ago

Collegium Announces the Closing of $980 Million Syndicated Credit Facility

Nov 12, 2025, 8:00 AM EST - 2 months ago

Collegium to Participate in Upcoming Investor Conferences

Nov 10, 2025, 4:27 PM EST - 2 months ago

Collegium Pharmaceutical: Another Solid Quarter

Nov 6, 2025, 10:06 PM EST - 2 months ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 2 months ago

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

Oct 30, 2025, 5:15 PM EDT - 2 months ago

Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

Oct 23, 2025, 8:00 AM EDT - 2 months ago

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 22, 2025, 8:00 AM EDT - 3 months ago

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

Oct 13, 2025, 8:00 AM EDT - 3 months ago

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

Sep 8, 2025, 5:03 PM EDT - 4 months ago

Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 5 months ago

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

Aug 7, 2025, 2:00 PM EDT - 5 months ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:30 AM EDT - 5 months ago

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

Jul 24, 2025, 8:00 AM EDT - 6 months ago

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 8:00 AM EDT - 6 months ago

Collegium Announces $150 Million Share Repurchase Program

Jun 30, 2025, 2:53 PM EDT - 7 months ago

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

May 12, 2025, 8:05 AM EDT - 8 months ago

Collegium Announces $25 Million Accelerated Share Repurchase Program

May 9, 2025, 2:04 AM EDT - 8 months ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 8 months ago

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Apr 24, 2025, 8:00 AM EDT - 9 months ago

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 1, 2025, 8:00 AM EDT - 10 months ago

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:00 AM EDT - 10 months ago

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 10 months ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Mar 10, 2025, 6:57 PM EDT - 11 months ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Mar 9, 2025, 4:07 AM EDT - 11 months ago

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Feb 27, 2025, 9:03 PM EST - 11 months ago

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 11 months ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 8:00 AM EST - 11 months ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

Collegium Provides 2025 Financial Guidance and Business Update

Nov 26, 2024, 8:00 AM EST - 1 year ago

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 14, 2024, 4:30 PM EST - 1 year ago

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Nov 8, 2024, 12:30 AM EST - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

Collegium Reports Record Third Quarter 2024 Financial Results

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 9:30 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Collegium Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 6:00 AM EDT - 1 year ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

May 29, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in Jefferies Global Healthcare Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Collegium Announces $35 Million Accelerated Share Repurchase Program

May 9, 2024, 7:32 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:02 PM EDT - 1 year ago

Collegium Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Mar 12, 2024, 5:00 AM EDT - 2 years ago

Top 10 Small-Cap Stocks (SA Quant)

ANIP APOG BLBD GCT PLMR RAMP RDCM

Feb 22, 2024, 9:52 PM EST - 2 years ago

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:09 PM EST - 2 years ago

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Feb 8, 2024, 8:00 AM EST - 2 years ago

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Nov 27, 2023, 8:00 AM EST - 2 years ago

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

Nov 7, 2023, 10:15 PM EST - 2 years ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

jewell69 Jan. 13 at 1:59 AM

Did everyone see that $BEAM was up 22.5% today 1/12/26 Now, new topic, thinking about $COLL losing -4.5% around Wednesday 1/7/26 Worth a trade if it hasn’t yet regained that dip ditto $BX

0 · Reply

jewell69 Jan. 9 at 6:34 PM

$COLL s 39. 46.04 around 22:50 pm 1/9 Day trade 4 small profit

0 · Reply

jewell69 Jan. 9 at 4:18 PM

0 · Reply

jewell69 Jan. 9 at 3:58 PM

0 · Reply

jewell69 Jan. 9 at 3:54 PM

0 · Reply

jewell69 Jan. 9 at 3:50 PM

0 · Reply

jewell69 Jan. 9 at 3:47 PM

0 · Reply

Stefan100 Dec. 30 at 2:28 PM

1 · Reply

jewell69 Dec. 25 at 1:17 AM

$COLL did everybody see it was up 6.5% today 12/24/25

2 · Reply

volflux Dec. 18 at 12:55 PM

$COLL

0 · Reply

JarvisFlow Dec. 9 at 3:37 PM

Barclays has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Overweight with a target price of 58.

0 · Reply

Estimize Nov. 24 at 1:03 PM

Wall St is expecting 2.14 EPS for $COLL Q4 [Reporting 02/19 BMO] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co

0 · Reply

KirRoyalTrader Nov. 23 at 10:02 PM

$UVE $INVA $COLL $APPN

0 · Reply

evanmedeiros Nov. 23 at 5:10 PM

Nice high tight flag setting up here in Collegium Pharmaceutical. Watchlists still loaded with pharma stocks as technology continues its sell off. Chart found from @InvestorsBusinessDaily MarketSurge https://research.investors.com/stock-quotes/nasdaq-COLL-inc-COLL.htm?utm_source=Evan_Medeiros&utm_medium=stocktwits&utm_campaign=SOCIAL+INFLUENCER&utm_id=SCINFLUENCER&utm_content=leaderboard#performance%3Fsrc=A00616 $COLL #IBDPartner

0 · Reply

ZacksResearch Nov. 21 at 1:14 PM

2025 could be the momentum shift $COLL investors have been waiting for. Bold buybacks, a refreshed board, and an expanding ADHD push are all lining up to make this a truly dynamic, transformative year. Full breakdown here 👉 https://www.zacks.com/stock/news/2794020/why-2025-is-a-dynamic-and-transformative-year-for-collegium?cid=sm-stocktwits-2-2794020-teaser-21968&ADID=SYND_STOCKTWITS_TWEET_2_2794020_TEASER_21968

0 · Reply

ZacksResearch Nov. 21 at 12:14 PM

$COLL outshines with a 53.4% YTD gain! 🚀 ✨ Q3 2025 adjusted EPS of $2.25 beats the Zacks Consensus Estimate of $1.88. 📊 Revenue for Q3 2025 hits $209.36M, topping consensus & improving from $159.3M a year ago. 💪 Zacks Rank #1 (Strong Buy) highlights their strategic growth initiatives. Discover the full growth story here 👉 https://www.zacks.com/stock/news/2794020/why-2025-is-a-dynamic-and-transformative-year-for-collegium?cid=sm-stocktwits-2-2794020-body-21967&ADID=SYND_STOCKTWITS_TWEET_2_2794020_BODY_21967

0 · Reply

JR603 Nov. 12 at 10:14 PM

$COLL Could this be a BO? It's tempting to cash out after all these LONG years ..... BUT what if it's going to be offered to be bought at a 50% premium? That would be just my luck!!!

1 · Reply

Itinerant Nov. 7 at 9:55 PM

$COLL I understand that some investors fear the risk of the opiod litigation and its potential damage to the valuation of COLL. I have added $500 million of such cost into the balance sheet of COLL, and I want to tell you that such a liability is not of serious consequence to the overall valuation of COLL. The company is substantially under valued and can absorb such a settlement cost without difficulty. Of course, I do not really know what such a settlement might prove to be. I am just guessing a number. But you get the idea. Having said that, the market will likely over react to any such settlement, as the market almost always over reacts. JMO

0 · Reply

MarkNewtonCMT Nov. 7 at 9:45 PM

$COLL Collegium Pharma (Gen.Drugs) popped this week out of a tight Cup and Handle formed back in early 2024 and one to certainly keep an eye on going forward. This @marketsurge chart by @IBDinvestors is on William O Neill's screen (85 stocks) & given Healthcare's success lately, still looks technically attractive on this high volume breakout. @InvestorsBusinessDaily

0 · Reply

jewell69 Nov. 7 at 6:58 PM

$COLL sold yesterday 11/6 on great earns day 11/06/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 51 $40.05 $0.01 $2,042.54 up even more today, friday 11/7/25 1:54 pm est 42.31 +another 4.06% for the day

0 · Reply

JarvisFlow Nov. 7 at 3:51 PM

Truist Securities has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Buy with a target price of 45 → 48.

0 · Reply

JarvisFlow Nov. 7 at 11:41 AM

HC Wainwright & Co. updates rating for Collegium Pharmaceutical ( $COLL ) to Action List Buy, target set at 44 → 46.

0 · Reply

Market Cap	1.52B
Revenue (ttm)	631.45M
Net Income (ttm)	69.19M
EPS (ttm)	N/A
PE Ratio	7.13
Forward PE	6.82
Profit Margin	10.96%
Debt to Equity Ratio	2.07

Volume	257,300
Avg Vol	555,246
Day's Range	N/A - N/A
Shares Out	31.61M
Stochastic %K	59%
Beta	0.60
Analysts	Strong Sell
Price Target	$53.17